ALLMedicine™ Respiratory Syncytial Virus Infection Center

Feb 3rd, 2023 - Respiratory syncytial virus (RSV) is the most common cause of acute respiratory tract infection in infants and young children often leading to severe disease requiring hospitalization. However, validated tools for systematic assessment of disease ...

Jan 21st, 2023 - Most observational population-based studies identify RSV by nasal/nasopharyngeal swab RT-PCR only. We conducted a systematic review and meta-analyses to quantify specimen and diagnostic testing-based under-ascertainment of adult RSV infection. EMB...

Jan 21st, 2023 - Little is known about the burden and outcomes of respiratory syncytial virus (RSV)-positive acute respiratory infection (ARI) in community-dwelling older adults. To assess the incidence of RSV-positive ARI before and during the COVID-19 pandemic, ...

Jan 16th, 2023 - To elucidate the impact of the COVID-19 pandemic on the epidemiology of other infectious diseases. We investigated the epidemiology of 36 communicable diseases during 2015-2021 in Japan and compared the number of cases in each disease between the ...

Dec 17th, 2022 - Clarifying the pathogenesis of asthma and/or identifying the specific pathway underlying oral asthma tolerance (OT) would be of great significance. In our previous study, promyelocytic leukemia zinc finger (PLZF), which reportedly regulates memory...

Jul 30th, 2014 - Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, ...

Oct 26th, 2022 - This is a randomized (study medication assigned to participants by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled, single-center study of JNJ 53718678 in healthy adult par...

May 16th, 2022 - JNJ-53718678 is an investigational respiratory syncytial virus (RSV) specific fusion inhibitor and is under development for the treatment of RSV infection, which results in an upper and/or lower respiratory tract illness. The primary hypothesis of...

Apr 1st, 2022 - A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult P...

Jul 23rd, 2021 - The purpose of this study is to assess a trend for the prophylactic efficacy of a single dose of 1*10^11 virus particles (vp) of adenovirus serotype 26 respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) administered intramuscularly t...

Apr 13th, 2021 - RSV is a leading cause of lower respiratory tract disease in infants. The primary hypothesis is that treatment of RSV-infected infants/children with lumicitabine (also known as JNJ-64041575 or ALS-008176) will decrease subsequent wheezing/asthma c...

Mar 26th, 2020 - For children exposed to acid-suppressant medications, such as proton pump inhibitors and histamine 2 receptor antagonists, during their first year of life, the risk for recurrent wheeze at age 3 is significantly elevated, researchers warn. "We are...

Aug 22nd, 2019 - LJUBLJANA, SLOVENIA – Fever of unknown origin and pneumonia are two clinical features useful in distinguishing between influenza and respiratory syncytial virus infection as the cause of hospitalization in infants and young children, Cihan Papan,.

Aug 22nd, 2019 - LJUBLJANA, SLOVENIA – Fever of unknown origin and pneumonia are two clinical features useful in distinguishing between influenza and respiratory syncytial virus infection as the cause of hospitalization in infants and young children, Cihan Papan,.

Oct 31st, 2017 - TORONTO – A test that only requires a maximum 2-hour wait for results was highly accurate at detecting influenza and respiratory syncytial virus infection in lung transplant patients, according to research presented at the CHEST annual meeting on.

Oct 10th, 2017 - Hypertonic Versus Normal Saline Nebulizer Treatments The goal of a recent study[1] was to evaluate whether nebulized hypertonic saline (3%) was more beneficial than nebulized normal saline (0.9%) in the treatment of infants presenting to the emerg...